ACE2 and malaria: CQ and HCQ, originally approved for, but not limited to, treatment of malaria, alter the glycosylation of angiotensin-converting enzyme 2 (ACE2), the S protein-binding receptor in SARS, thereby indirectly interfering with the S protein-host receptor interaction in SARS-CoV and SARS-CoV-2.